INS and type 2 diabetes mellitus: Improved oral glucose tolerance in patients with type 2 diabetes without affecting insulin release by affecting the liver, leading to decreased hepatic glucose output, by regulating enzymes involved in gluconeogenetic and glycogenolytic processes